Efficacy of Tofacitib, a JAK/STAT inhibitor, in the treatment of septic infection complicated with inflammatory storm in children

A multicenter cohort study of the efficacy of tofatib, a JAK/STAT inhibitor, in children with septic infection associated with inflammatory storms

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100044111

Enrollment

Unknown

Registered

2021-03-11

Start date

2021-04-01

Completion date

Unknown

Last updated

2021-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sepsis

Interventions

control group:Regular treatment

experimental group:Regular plus Tofacitib

Eligibility

Sex/Gender

All

Age

No minimum to 18 Years

Inclusion criteria

Inclusion criteria: 1.Children between 0 and 18 years old. 2.Sepsis.Patients were included who meet the International Guide to the 2020 campaign to Save sepsis: management of septic shock and sepsis-related organ dysfunction in children.

Exclusion criteria

Exclusion criteria: 1.Notifiable infectious diseases. 2.The researcher believes that he is not suitable to participate in other situations in this study. 3.Participants in other clinical trials in the same period. 4.Immunodeficiency children. 5.Immunosuppression. 6.Solid tumors or hematologic tumors.

Design outcomes

Primary

Measure	Time frame
Clincial outcome;	—

Secondary

Measure	Time frame
28-day all-cause mortality;Cytokine level;	—

Countries

China

Contacts

Public ContactYuFeng Zhou

Children's Hospital of Fudan University

yfzhou1@fudan.edu.cn+86 21-64932907

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026